Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. A, 1997, Pages 145-151

  Linden, Peter K ^a   Pasculle, Anthony W ^a   McDevitt, David ^a   Kramer, David J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DALFOPRISTIN; QUINUPRISTIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIOSTASIS; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; FEMALE; FOLLOW UP; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECIUM; FEMALE; FOLLOW-UP STUDIES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VANCOMYCIN; VIRGINIAMYCIN;

EID: 0031010344     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_1.145     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. (1993). Nosocomial enterococci resistant to vancomycin - United States 1989-1993. Morbidity and Mortality Weekly Report 42, 597-9.
2. Linden, P. K., Pasculle, A. W., Manez, R., Kramer, D. J., Fung, J. J., Pinna, A. D. et al.(1996). Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clinical Infectious Diseases 22, 663-70.
3. Montecalvo, M. A., Horowitz, H., Wormser, G. P., Seiter, K. & Carbonaro, C. A. (1995). Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 39, 794.
4. Morris, A. H., Reilly, J. P., Edelstein, P. H., Bronnan, P. J. & Schuster, M. G. (1995). Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clinical Infectious Diseases 20, 1137-44.
5. Shlaes, D. M., Etter, L. & Gutmann, L (1991). Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin. Antimicrobial Agents and Chemotherapy 35, 776-9.
6. Hayden, M. K., Trenholme, G. M., Schultz, J. E. & Sahm, D. F. (1993). In vivo development of teicoplanin resistance in a Van B Enterococcus faecium isolate. Journal of Infectious Diseases 167, 1224-7.
7. Lynn, W. A., Clutterbuck, E., Want, S., Markides, V., Lacey, S., Rogers, T. R. et al. (1994). Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 344, 1025-6.
8. Facklam, R. R. & Sahm, D. F. (1995). Enterococcus. In Manual of Clinical Microbiology, 6th edn (Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H., Eds), pp. 308-14. American Society for Microbiology, Washington, DC.
9. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA.
10. Low, D. E. (1995). Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microbial Drug Resistance 3, 223-34.
11. Swenson, J. M., Ferraro, M. J., Sahm, D. F., Tenover, F. C. and the Working Group on Enterococci. (1993). Recommended guidelines for detection of high-level aminoglycoside resistance enterococci. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1990. Abstract 263, p. 167, American Society for Microbiology, Washington DC.
12. Noskin, G. A., Peterson, L. R. & Warren, J. R. (1995). Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clinical Infectious Diseases 20, 296-301.
13. Hoge, C. W., Adams, J., Buchanan, B. & Sears, S. D. (1991). Enterococcal bacteremia: to treat or not to treat, a reappraisal. Reviews of Infectious Diseases 12, 600-5.
14. Gullberg, R. M., Homann, S. R. & Phair, J. P. (1989). Enterococcal bacteremia: analysis of 75 episodes. Reviews of Infectious Diseases 11, 74-85.
15. Barrall, D. T., Kenney, P. R., Slotman, G. J. & Burchard, K. W. (1985). Enterococcal bacteremia in surgical patients. Archives of Surgery 103, 57-63.
16. Bryan, C. S., Reynolds, K. L. & Brown, J. J. (1985). Mortality associated with enterococcal bacteremia in surgical patients. Surgery, Gynecology and Obstetrics 160, 557-61.
17. Murray, B. E. (1995). What can we do about vancomycin-resistant enterococci? Clinical Infectious Diseases 20, 1134-6.
18. Moellering, R.C. (1991). The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. Journal of Antimicrobial Chemotherapy 28, 1 -12.
19. Furlong, W. B. & Bompart, F. (1994). Therapy for enterococci with van A/van B resistance patterns using RP 59500 (quinupristin/dalfopristin). In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract M66, p. 261. American Society for Microbiology, Washington, DC.
20. Nachtman, A., Verma, R. & Egnor, M. (1995). Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microbial Drug Resistance 1, 95-6.
21. Perri, M. B., Dembry, L. M. & Zervos, M. J. (1994). Comparative in vitro activity of RP 57669/RP 54476: RP 59500 against multi-resistant enterococci. In Program and Abstracts of the Second International Conference on the Macrolides, Azalides and Streptogramins, Venice, Italy, 1994.
22. Freeman, C., Robinson, A., Cooper, B., Mazens-Sullivan, M., Quintiliani, R. & Nightingale, C. (1995). In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagnostic Microbiology and Infectious Disease 21, 47-50.
23. Cormican, M. G., Johnson, D. M. & Jones, R. N. (1996). Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against Enterococcus species. Diagnostic Microbiology and Infectious Disease 24, 59-60.
24. Collins, L. A., Malanoski, G. J., Eliopoulos, G. M., Wennersten, C. B., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrobial Agents and Chemotherapy 37, 598-601.